Company / Accounts Receivable
AMICUS THERAPEUTICS, INC. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$115.3M
FY2025
5-year range
$52.7M / $115.3M
FY2021-FY2025
Trend
+14.1%
vs FY2024
Sector context
#51 of 113
Health Care
What the data says
At $115M, AMICUS THERAPEUTICS, INC.'s accounts receivable ranks #51 of 113 in the Health Care sector. Accounts Receivable has increased for 9 consecutive years, from $1M in FY2016 to $115M in FY2025.
Based on SEC 10-K filings.
$115M in FY2025 with a 5-year CAGR of +19.7%.
Improved from $88M to $115M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +20.3%
- 5-Year CAGR
- +19.7%
- 10-Year CAGR
- -
Sector benchmark
#51 of 113 in Health CareTop 45% of 113This company $115.3M Sector average $1.1B
▼
-89.9% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s accounts receivable has grown for 9 consecutive years.
- 5-year CAGR of +19.7%, indicating consistent growth.
- In FY2025, accounts receivable increased 14.1% year-over-year.
- Ranks #51 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $115.3M | +14.1% |
| FY2024 | $101.1M | +15.4% |
| FY2023 | $87.6M | +32.4% |
| FY2022 | $66.2M | +25.7% |
| FY2021 | $52.7M | +12.3% |
| FY2020 | $46.9M | +41.0% |
| FY2019 | $33.3M | +51.6% |
| FY2018 | $22.0M | +132.1% |
| FY2017 | $9.5M | +625.8% |
| FY2016 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026